Table 1. Test performance of HPV testing and cytology for detection of posttreatment CIN 2 or worse.
| Testing methods | No. of women included in analysis | No. of test-positive women (colposcopy referral rate, %) | Detection of recurrent or residual CIN 2 or worse | |||
|---|---|---|---|---|---|---|
| Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | |||
| High-risk HPV test* | 5,322 | 1,119 (21.0) | 0.91 (0.88-0.94) | 0.83 (0.82-0.84) | 0.28 (0.26-0.31) | 0.99 (0.99-1.00) |
| HPV genotyping† | 1,667 | 399 (23.9) | 0.89 (0.82-0.94) | 0.83 (0.81-0.85) | 0.28 (0.24-0.33) | 0.99 (0.98-0.99) |
| Cytology‡ | 3,656 | 813 (22.2) | 0.74 (0.68-0.79) | 0.85 (0.83-0.86) | 0.25 (0.22-0.28) | 0.98 (0.97-0.98) |
| Co-testing§ | 2,287 | 645 (28.2) | 0.92 (0.87-0.96) | 0.76 (0.74-0.78) | 0.20 (0.17-0.23) | 0.99 (0.99-1.00) |
CIN 2, cervical intraepithelial neoplasia grade 2; HPV, human papillomavirus; NPV, negative predictive value; PPV, positive predictive value.
*High-risk HPV tests, all HPV DNA detection assays detecting at least 13 carcinogenic HPV genotypes. †HPV genotyping, detection of HPV persistence between pre- and posttreatments. ‡Cytology, atypical squamous cells of undetermined significance threshold. §Co-testing, combination test of both high-risk HPV test and cytology